Biofrontera reports preliminary Q4 2022 revenue of ~$10.2-10.4M, up 12% YoY; FY2022 record $28.7-28.9M

Biofrontera Inc.

2023-FY EPS reported -$0.61 revenue$28,674,000

Preliminary Q4 2022 revenue $10.2-10.4M, an increase of approximately 12% vs Q4 2021.
Full year 2022 revenue of $28.7-28.9M, a record high and up ~20% compared to 2021.
CEO Erica Monaco cites continued expansion of Ameluz-PDT for actinic keratosis as driver.
Final Q4 and FY2022 financial results expected in March 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biofrontera Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $10.2 million to $10.4 million.

Period: fourth quarter and year ended December 31, 2022
Revenue: $10.2 million to $10.4 million
Result: preliminary results

Exact text from the filing

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022. Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021. These projections result in 2022 revenue of approximately $28.7 million to $28.9 million, a record high and up approximately 20% compared with 2021.

View on SEC.gov

Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-000908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.